financetom
Business
financetom
/
Business
/
Roku's 2024 Results, 2025 Outlook Signal Focus on Expanding Profitability, Wedbush Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Roku's 2024 Results, 2025 Outlook Signal Focus on Expanding Profitability, Wedbush Says
Feb 14, 2025 7:45 AM

10:22 AM EST, 02/14/2025 (MT Newswires) -- Roku's ( ROKU ) 2024 results and 2025 outlook demonstrate its focus on expanding profitability as it continues to grab market share, Wedbush said in a note Friday.

The company is also "well-positioned" as a platform as advertisers are switching to shoppable ad integration on connected TV, analysts led by Alicia Reese added.

Investors are likely to "reward" Roku ( ROKU ) for adopting a balanced strategy as it expands operations globally, and grows its platform and The Roku Channel's ad capabilities, all while retaining "expense discipline" to increase free cash flow, the analysts said.

"We expect Roku ( ROKU ) to benefit from rising ad demand, driven by its new DSP partnerships, new high-quality inventory, improved targeting, sports-adjacent ads, and various price points to meet advertisers' needs," the note said.

Wedbush raised Roku's ( ROKU ) price target to $125 from $100 and maintained an outperform rating.

Shares of the company were up over 14% in recent Friday trading.

Price: 99.17, Change: +12.37, Percent Change: +14.25

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BioNTech, Duality Biologics Receive FDA Fast-Track Designation for Prostate Cancer Drug
BioNTech, Duality Biologics Receive FDA Fast-Track Designation for Prostate Cancer Drug
Jun 24, 2024
08:05 AM EDT, 06/24/2024 (MT Newswires) -- BioNTech (BNTX) and Duality Biologics said Monday that the US Food and Drug Administration has granted fast-track designation for their experimental drug, BNT324/DB-1311, to treat metastatic castration-resistant prostate cancer. The designation, which facilitates the development and expedites the review of new drugs and vaccines, was based on preliminary safety and efficacy data from...
Altair Engineering Collaborates with HP
Altair Engineering Collaborates with HP
Jun 24, 2024
08:06 AM EDT, 06/24/2024 (MT Newswires) -- Altair Engineering ( ALTR ) said on Monday that it has signed an agreement to enhance its Material Data Center by incorporating HP's (HPQ) proprietary material information. The company said the partnership between Altair and HP would bridge the gap between the design and production of 3D-printed parts and enable designers and engineers...
UBS to sell partial stake of a joint venture to Beijing state asset manager
UBS to sell partial stake of a joint venture to Beijing state asset manager
Jun 24, 2024
BEIJING/HONG KONG, June 24 (Reuters) - UBS is selling a partial stake in one of its securities joint ventures to Beijing State-owned Asset Management (BSAM), a key step for the Swiss bank as it consolidates operations in China after its merger with Credit Suisse. Its joint venture partner Founder Securities said in a filing on Monday that Founder would offload...
FirstService Residential Buys San Francisco-Based CitiScape Property Management
FirstService Residential Buys San Francisco-Based CitiScape Property Management
Jun 24, 2024
08:06 AM EDT, 06/24/2024 (MT Newswires) -- FirstService ( FSV ) said on Monday that it bought CitiScape Property Management Group, a full-service community association management firm in the San Francisco metropolitan market. The financial terms of the deal were not disclosed. CitiScape's existing executive team will continue to head the day-to-day operations. FirstService's ( FSV ) stock rose over...
Copyright 2023-2026 - www.financetom.com All Rights Reserved